title: Cardiovascular safety of methylphenidate should also be considered in adults.
authors.affiliation: Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Toulouse, France.
authors.forename: François
authors.initials: F
authors.lastname: Montastruc
authors.affiliation: Service de Cardiologie, Clinique des Cèdres Toulouse, Toulouse, France.
authors.forename: Guillaume
authors.initials: G
authors.lastname: Montastruc
authors.affiliation: Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de PharmacoVigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Pharmacopôle Midi-Pyrénées, INSERM UMR 1027, CIC INSERM 1436, Toulouse, France.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Montastruc
authors.affiliation: Service Universitaire de Psychiatrie de l'Enfant et de l'Adolescent, Centre Hospitalier Universitaire Toulouse, UMR 1027 Inserm-Université Paul Sabatier, Toulouse, France.
authors.forename: Alexis
authors.initials: A
authors.lastname: Revet
mesh_terms: D000367:Age Factors; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008774:Methylphenidate / Q000009:adverse effects*; D008875:Middle Aged; D018879:Ventricular Premature Complexes / Q000139:chemically induced*
chemical_list: D000697:Central Nervous System Stimulants; D008774:Methylphenidate